Table 2.
Summary of Adverse Events (AEs) during Cycle 1 in the Dose Escalation Cohort (n = 26)
| Escalation (n = 26) AE Grades |
||||
|---|---|---|---|---|
| G1&2 | G3 | G4 | G5 | |
| General disorder | ||||
| Fatigue | 6 (23.1%) | 1 (3.8%) | 0 | 0 |
| Hematologic disorder | ||||
| Neutropenia | 0 | 0 | 2 (7.7%) | 0 |
| Cardiac disorders | ||||
| Hypertension | 0 | 1 (3.8%) | 0 | 0 |
| Troponin increased | 0 | 1 (3.8%) | 0 | 0 |
| Gastrointestinal disorders | ||||
| Abdominal pain | 0 | 1 (3.8%) | 0 | 0 |
| Constipation | 0 | 2 (7.7%) | 0 | 0 |
| Diarrhea | 4 (15.4%) | 1 (3.8%) | 0 | 0 |
| Metabolic disorder | ||||
| Hypophosphatemia | 0 | 1 (3.8%) | 0 | 0 |
| Inappropriate antidiuretic hormone secretion | 0 | 0 | 1 (3.8%) | 0 |
| Pulmonary disorder | ||||
| Hypoxia | 0 | 1 (3.8%) | 0 | 0 |
| Miscellaneous | ||||
| Maculopapular rash | 0 | 1 (3.8%) | 0 | 0 |
| Musculoskeletal pain | 0 | 1 (3.8%) | 0 | 0 |
Subjects with AEs in multiple severity ratings are counted once under the maximum severity.
The table summarizes grade 1 and grade 2 AEs occurring in >=20% of subjects and all grade 3 or higher AEs.